Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu LT, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Zhai Y.
Ailawadhi S, et al. Among authors: liang e.
Clin Cancer Res. 2023 Jul 5;29(13):2385-2393. doi: 10.1158/1078-0432.CCR-22-3321.
Clin Cancer Res. 2023.
PMID: 37074726
Free PMC article.